
Diabetes: What patients want
It is a well-known fact that the prevalence of type 2 diabetes (T2DM) is increasing worldwide. According to the International…


Do fixed-ratio combinations herald the end of basal insulin alone in T2DM?
In their study investigating different strategies to initiate and intensify basal insulin treatment in patients with type 2 diabetes (T2DM),…


Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus: Delving deeper
GLP-1 RA studies showed a macrovascular disease benefit.


REWINDING REWARD in the management of type 2 diabetes
SGLT2-inhibitors have a major beneficial effect on reducing heart failure


Combining for effective simplicity
In this article we will look at key lessons learned from landmark studies.


Specialist Forum October 2021 issue CPDs
Below you will find links to CPD articles produced for Specialist Forum‘s October 2021 issue.


Superior HbA1c reduction with Solimix
Type 2 diabetes (T2DM) is a progressive disease, associated with microvascular complications such as retinopathy, nephropathy, and neuropathy, as well…

Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus
Dr Nqoba Tsabedze, Academic & Clinical Head – Division of Cardiology, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand


Controlling blood sugar levels optimally
Type 2 diabetes (T2DM) is a major global public health problem. According to the World Health Organisation, about 422 million…

Empagliflozin and metformin to reduce cardiac risk in type 2 diabetes?
Type 2 diabetes is a major risk factor for cardiovascular disease. Having both type 2 diabetes and cardiovascular disease increases…

The challenge of diabetes management in LMICs
In low-and middle-income countries, especially in Sub-Saharan Africa, noncommunicable diseases (NCDs) such as diabetes are placing a growing strain on…


Achieving optimal glycaemic control with insulin lispro pens
A rise in body weight or worsening insulin tolerance in diabetic patients nearly always results in an increase in their…


New hope for obesity patients
Liraglutide, which has consistently shown 5%-10% of weight-loss when combined with diet and physical activity, has been given the go-ahead…
